Boston Scientific's Buying Spree Continues, This Time in EP

This month's $115 million cash deal to acquire electrophysiology company Cardiac Pathways Corp., makes five acquisitions for Boston Scientific already this year. Boston's dealmaking flurry is particularly notable given the relative inactivity of other large device companies on the acquisition front, and the cold shoulder the public market has given to the device sector. This deal reflects Boston's renewed commitment to electrophysiology, an area the company was thinking about exiting just a couple of years ago despite having a market-leading product. But it still remains to be seen whether this recent string of deals can turn around Boston Scientific and boost its flagging stock price.